External Quality Assessment for KRAS Testing Is Needed: Setup of a European Program and Report of the First Joined Regional Quality Assessment Rounds

The use of epidermal growth factor receptor–targeting antibodies in metastatic colorectal cancer has been restricted to patients with wild-type KRAS tumors by the European Medicines Agency since 2008, based on data showing a lack of efficacy and potential harm in patients with mutant KRAS tumors. In...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Bellon, Ellen, Ligtenberg, Marjolijn J.L., Tejpar, Sabine, Cox, Karen, de Hertogh, Gert, de Stricker, Karin, Edsjö, Anders, Gorgoulis, Vassilis, Höfler, Gerald, Jung, Andreas, Kotsinas, Athanassios, Laurent-Puig, Pierre, López-Ríos, Fernando, Hansen, Tine Plato, Rouleau, Etienne, Vandenberghe, Peter, van Krieken, Johan J.M., Dequeker, Elisabeth
Format: Artigo
Jezik:Inglês
Izdano: AlphaMed Press 2011
Teme:
Gastrointestinal Cancer
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3228116/
https://ncbi.nlm.nih.gov/pubmed/21441573
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0429
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items